Fresenius Medical Care is refining its commercial strategy in China to support long-term growth and strengthen its market position. The company plans to tailor its portfolio more closely to local needs and focus on innovation. China accounts for approximately 6–7% of Care Enablement segment revenues.
The company will discontinue local production and sales of its 4008A hemodialysis system and exit its peritoneal dialysis business in China. It will increase its focus on innovative technologies for in-center dialysis and critical care.
Fresenius expects to incur one-time costs related to these portfolio decisions in the third quarter of 2026. It will treat the costs as a special item.